Default company panoramic image
Aef4fea7 a202 44c9 8ed4 e2c9896feb71

thorenco medical isotopes llc

Thorenco will be the premier supplier of scarce isotopes used as active pharmaceutical ingredients in new, more effective cancer drugs.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Website

Company Summary

New cancer drugs depend on a reliable supply of isotopes that are now in short supply. Using its proprietary production technology, Thorenco will manufacture isotopes used in new drugs that treat prostate cancer and other cancers that spread to bone. These isotopes can be used to treat primary tumors as well. There will be no isotope shortage for new cancer drugs after Thorenco becomes part of the global supply chain.


  • Default avatar
    Charles St. George Holden

    Charles "Rusty" Holden practiced law from 1975 to 2004. He received a BA in political science from University of California, Berkeley in 1972 followed by a JD from Hastings College of the Law in 1975. In 2005 he contracted with National Laboratories to perform computational studies concerning thorium fuels and production of medical isotopes. The computational studies developed ways to make medical isotopes with the guidance of Dr. Schenter.

  • Default avatar
    Michael Ullman

    Michael Ullman has more than 30 years of experience in the pharmaceutical and biotechnology sectors. Mr. Ullman was Managing Director at Burrill & Company, a life sciences venture capital firm. Mr. Ullman headed Biovector Therapeutics, Liposome Technology /SEQUUS Pharmaceuticals, Inc. He started at Bristol-Myers Squibb Corporation. He received BS in Pharmaceutical Science from Drake University in 1967 and MBA from University of Illinois in 1971.

  • Default avatar
    Phil Husby

    Phil Husby has over 40 years of professional experience providing financial, accounting and tax services to technology companies. He is a CPA has held CFO positions at many public and private companies and has extensive international experience. He has been associated with KPMG, Tatum LLC, Big Fix, Inc, Iomega and Ogden Corporation. He received his BS in accounting from University of San Francisco in 1968 and MBA from US Berkeley.

  • Default avatar
    Richard Wittman Ph.D.
    CTO (Acting)

    Dr. Rick Wittman holds a doctorate in theoretical nuclear physics from Rensselaer Polytechnic Institute competed in 1986. He has deep experience with predictive modeling and data analysis of physical systems.. He is responsible for performing isotope production calculations and provide modeling support to the Radiochemical Processing Laboratory at Pacific Northwest National Laboratory. Dr. Wittman has performed computational studies supporting Th


  • Default avatar
    David Niebauer
    Default avatar
    James Hastings